Dr. Raphael (Rafi) Hofstein is president and CEO of MaRS Innovation (MI) – the commercialization agent for an exceptional research discovery pipeline stemming from 16 leading Ontario academic institutions. As a single entry point to annual member research and development activity of $1B, MI provides a gateway for investors and licensees who wish to access Ontario’s technology assets.
During the 2012 BIO convention in Boston, Dr. Hofstein blogged about how CQDM of Montreal and MaRS Innovation of Toronto had teamed up to ...
TORONTO, April 22, 2013 — MaRS Innovation, a Centre of Excellence for Commercialization and Research, today announced the formation of a strategic partnership with Pfizer Inc. to advance early-stage technologies related to human health in therapeutics and diagnostics.
Through this collaboration, MaRS Innovation and Pfizer will jointly identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals.
“There’s growing consensus that transferring technologies from the university lab ...
Stem Cell Therapeutics Corp. (TSX-V: SSS), a biopharmaceutical company developing cancer stem cell-related technologies, has signed a definitive license agreement with University Health Network (UHN), Toronto, Canada.
The agreement, developed in collaboration with MaRS Innovation, provides Stem Cell Therapeutics (SCT) with exclusive worldwide rights to an innovative clinical cancer stem cell program.
This announcement builds upon the existing stem cell program agreement between MI, Stem Cell Therapeutics and UHN, which was announced in November 2012.
The initial consideration of $1.6 million for the UHN ...
TORONTO, ON (Feb. 19, 2013) – XLV Diagnostics Inc., a start-up company working to commercialize a faster, cheaper and better digital mammography technology, has received a $500,000 investment from FedNor.
Over 600 million women living in developing countries have inadequate access to breast screening for early cancer detection. In the developed world, many radiology departments are replacing traditional film and screen systems with digital technologies. In both cases, better digital mammography technology promises to solve logistical challenges and save money.
XLV’s solution has ...
Each year, 5,000 children in North American hospitals experience code-blue incidents; a code blue is an event where patients require immediate resuscitation.
One quarter of these incidents result in death, and Bedside Clinical Systems (BCS) seeks to drastically improve this statistic by launching its flagship solution, Bedside Paediatric Early Warning System (BedsidePEWS™).
“BedsidePEWS™ is a unique software solution that helps hospital clinicians to identify deteriorating children early, giving them a window of opportunity to intervene and potentially avoid code blue incidents,” says Rajesh ...
Welcome to the beta version of the MaRS Innovation website.
We have refreshed the site's design to make better use of its existing functionality while showcasing our projects.
The new design includes these additions and changes: (more…)
The University of Toronto's news site has posted a brief snapshot of Toronto's entrepreneurial scene, highlighting the university's historical and current innovative strengths.
Here's a brief excerpt:
Entrepreneurs don’t have to be in Silicon Valley to become the next great business success story. Toronto now ranks fourth among the world’s top 25 start-up ecosystems, according to Start-up Genome, a project that maps the success rates of start-ups. Toronto ranks just behind Silicon Valley, New York City and London. (more…)
MaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek) have announced a strategic partnership to co‐develop, and bring to the Chinese market, a novel therapeutic cream aimed at reducing scar formation post surgery.
This project was covered in The Globe and Mail on May 7, 2012.